• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Sarepta to Sell Up to $225 Million of Stock

    Sarepta to Sell Up to $225 Million of Stock

  2. UPDATE: Charting the S&P 500's bullish-leaning holding pattern ahead of the Fed

    UPDATE: Charting the S&P 500's bullish-leaning holding pattern ahead of the Fed

  3. UPDATE: Charting the S&P 500's bullish-leaning -2-

    UPDATE: Charting the S&P 500's bullish-leaning -2-

  4. UPDATE: S&P 500 survives major technical test, -2-

    UPDATE: S&P 500 survives major technical test, -2-

  5. UPDATE: S&P 500 survives major technical test, bull trend (tenuously) intact

    UPDATE: S&P 500 survives major technical test, bull trend (tenuously) intact

  6. UPDATE: S&P 500 survives major technical test, bull trend (tenuously) intact

    UPDATE: S&P 500 survives major technical test, bull trend (tenuously) intact

  7. UPDATE: S&P 500 survives major technical test, -2-

    UPDATE: S&P 500 survives major technical test, -2-

  8. Nasdaq nails major support, S&P 500 holds the range

    Nasdaq nails major support, S&P 500 holds the range

  9. Nasdaq nails major support, S&P 500 holds the -2-

    Nasdaq nails major support, S&P 500 holds the -2-

  10. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.